For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
3
views
40
references
 Top references
cited by
2
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,519
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d13978121e328">Several programmed death ligand-1 (PD1/L1) immune checkpoint inhibitors (ICIs) are approved in urothelial carcinoma (UC). </p>

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          Hyuna Sung, Jacques Ferlay, Rebecca Siegel … (2021)
          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
          Article 0 comments Cited 29819 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Conducting Meta-Analyses inRwith themetaforPackage

            Wolfgang Viechtbauer (2010)
            Article 0 comments Cited 2888 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

              Joaquim Bellmunt, Ronald de Wit, David J Vaughn … (2017)
              New England Journal of Medicine, 376(11), 1015-1026
              Article 0 comments Cited 858 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Sabin Tataru: (View ORCID Profile)
                Pasquale Dolce: (View ORCID Profile)
                Giuseppe Lucarelli: (View ORCID Profile)
                Daniela Terracciano: (View ORCID Profile)
                Gian Maria Busetto: (View ORCID Profile)
                Francesco Del Giudice: (View ORCID Profile)
                Luigi Schips: (View ORCID Profile)
                Francesco Lasorsa: (View ORCID Profile)
                Luca Scafuri: (View ORCID Profile)
                Journal
                Title: Clinical Genitourinary Cancer
                Abbreviated Title: Clinical Genitourinary Cancer
                Publisher: Elsevier BV
                ISSN (Print): 15587673
                Publication date Created: October 2023
                Publication date (Print): October 2023
                Volume: 21
                Issue: 5
                Pages: 574-583
                Article
                DOI: 10.1016/j.clgc.2023.05.017
                PubMed ID: 37419854
                SO-VID: 7b307df1-48f2-4c88-b4a4-6f00e98e42ea
                Copyright © © 2023
                License:

                https://www.elsevier.com/tdm/userlicense/1.0/

                https://doi.org/10.15223/policy-017

                https://doi.org/10.15223/policy-037

                https://doi.org/10.15223/policy-012

                https://doi.org/10.15223/policy-029

                https://doi.org/10.15223/policy-004

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,519

                See all similar

                Cited by2

                See all cited by

                Most referenced authors1,330

                See all reference authors